Mid-Day Market Update: Gold Down 1%; Immix Biopharma Shares Spike Higher
Midway through trading Monday, the Dow traded up 0.18% to 36,402.21 while the NASDAQ rose 0.75% to 15,762.21. The S&P also rose, gaining 0.23% to 4,776.99.
35 Stocks Moving In Monday’s Mid-Day Session
Gainers
Immix Biopharma, Inc. (NASDAQ: IMMX) shares climbed 110.3% to $7.32. The FDA granted Rare Pediatric Disease (RPD) designation to newly listed Immix Biopharma's IMX-110 for rhabdomyosarcoma, a form of pediatric cancer.
Why Applied Therapeutics Shares Are Falling Today
Applied Therapeutics (NASDAQ: APLT) is trading significantly lower Monday after the company said it would not immediately submit a new drug application for its AT-007 for treatment of galactosemia.
Mid-Morning Market Update: Markets Edge Higher; Tesla Q4 Deliveries Top Estimates
Following the market opening Monday, the Dow traded up 0.11% to 36,378.68 while the NASDAQ rose 0.18% to 15,673.75. The S&P also rose, gaining 0.11% to 4,771.56.
Applied Therapeutics To Hold Filing FDA Application For AT-007 In Rare Metabolic Disorder
Following discussions with the FDA, Applied Therapeutics Inc (NASDAQ: APLT) has
Applied Therapeutics to Hold on Submitting a New Drug Application for its AT-007 for Treatment of Galactosemia Pending Additional Discussions with the FDA
The ongoing ACTION-Galactosemia Kids Phase 3 study is evaluating the impact of AT-007 treatment vs. placebo on clinical outcomes over time, including cognition, speech, behavior and motor skills. Clinical outcomes are
Applied Therapeutics Announces Initiation Of Registrational Phase 2/3 Study of AT-007 In SORD Deficiency
Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting season and ahead of the holiday week.
